Electronic cigarettes, which are not licensed for sale in Taiwan, are widely available online, according to a Taipei Times story citing an investigation by Taipei city’s Department of Health.
The department’s first probe into electronic cigarette availability found 318 different models or related products available online.
The unlicensed distribution and production of all products containing nicotine is prohibited under the Pharmaceutical Affairs Act.
Even marketing nicotine-free products as aids to quit smoking is illegal under the act.
The department said that while electronic cigarettes were rarely sold openly in stores, they were sometimes available from night market vendors operating under the cover of selling cigarette lighters and other products.
US-based LOGIC Technology is preparing to launch its LOGIC PRO Advanced Vapor Systems: what it describes as ‘the first-of-its-kind “closed-system” vaporizing device ever to hit the market’.
The new systems are said to ‘work in conjunction with revolutionary pre-filled, sealed eliquid capsules to provide a heightened level of taste, consistency and value to adult consumers’.
‘Building on a long history of premium and innovative product development, LOGIC Technology designed the LOGIC PRO to work with specialized, proprietary disposable capsules that are only available for purchase at LOGIC’s partner retailers; this not only allows retailers to recapture and maintain sales, it also enhances the vaping experience for the adult consumer,’ the company said in a press note.
‘Beyond providing consistent quality taste, these sealed eliquid capsules don’t produce the messy and costly spillage associated with traditional drip eliquid.’
The new systems are due to be made available in retail outlets by the winter. “We are thrilled to bring a product to market that fills the need of our adult consumers,” said Miguel Martin, president of LOGIC Technology.
“With the amount of money that is lost by retailers from online eliquid sales, we are pleased to offer our retailers and partners a piece of that market share.”
The CEO of Lorillard is set to receive more than $44 million following the planned $25 billion merger of Lorillard with Reynolds American, according to a story by Associated Press writer Michael Felberbaum published by ABC News and citing regulatory filings with the Securities and Exchange Commission.
Murray Kessler is one of several Lorillard executives set to receive compensation if they lose their jobs after the deal closes.
The bulk of Kessler’s $44.7 million would come in the form of a payout of stock awards worth $32.8 million.
He’d receive also $10.6 million in cash, which amounts to three times his base salary and annual bonus.
Last fiscal year, Kessler’s pay was increased by 21 percent to $10.3 million, according to an AP analysis of a regulatory filing.
Upon completion of the deal, Kessler, who became CEO of Lorillard in September 2010, will get a seat on Reynolds’ board of directors, which will come with additional pay.
Despite what were described as increased efforts by the tobacco industry to undermine the World Health Organization’s Framework Convention on Tobacco Control (FCTC), important decisions were passed by the sixth meeting of the Conference of the Parties (COP6) to the FCTC meeting in Moscow last week, according to a HealthCanal.com story.
One of the first decisions approved by COP6 was in relation to Article 6 guidelines, which concern tax measures aimed at reducing demand for tobacco. ‘The regulations provide for tax rates to be monitored, increased and adjusted annually, taking into account inflation and income growth,’ the story said. ‘At the same time, all tobacco products should be taxed in a comparable way to prevent substitutions of the use of one product with another.’
COP6 adopted also a decision on electronic nicotine (and non-nicotine) delivery systems (ENDS). ‘This rather novel product was first launched by independent companies, but many of them are now being controlled by multinational tobacco companies,’ the story said. ‘The decision acknowledges the need for regulations along the lines of policies concerning other tobacco products, including banning or restricting promotion, advertising and sponsorship of ENDS.’
COP6 noted that the heaviest burden of tobacco related diseases was borne by the most vulnerable population groups, and the Moscow Declaration called on the parties to strengthen international collaboration on tobacco control so as to reduce tobacco use by 30 per cent by 2025.
Some of the other decisions taken concerned:
- Proposals for the regulation of smokeless tobacco and water pipe products;
- Recommendations for entry into force of the Protocol to Eliminate Illicit Trade in Tobacco Products;
- A commitment to continue to work on Article 19, which concerns the liability of tobacco companies;
- Principles concerning articles 17 and 18, which address sustainable alternative livelihoods for tobacco growers;
- Trade and investment issues related to FCTC implementation;
- Assessment of the FCTC’s impact on the ‘tobacco epidemic’.
The HealthCanal story is at: http://www.healthcanal.com/public-health-safety/56372-who-tobacco-treaty-makes-significant-progress-despite-mounting-pressure-from-tobacco-industry.html.
Tobacco and tobacco manufacturers are in the vanguard of efforts to fight Ebola.
According to a NASDAQ story, US-based Mapp Biopharmaceutical has been working on an Ebola vaccine that is being produced in tobacco leaves at Kentucky Bioprocessing, which is owned by Reynolds American.
Until recently, Mapp’s production of its ZMapp Ebola vaccine has been limited and, prior to the latest Ebola outbreak, output totaled what was needed for pre-clinical and early stage human trials. That meant that only a handful of ZMapp doses were available when healthcare providers came knocking on Mapp’s door asking for an emergency supply.
So Mapp, policymakers and non-profits such as the Bill and Melinda Gates Foundation are hard at work on ways to ramp up that production. For example, the US Department of Health and Human Services has put up $25 million this year to help Mapp move forward and, according to the New York Times, the department is talking to Caliber Biotherapeutics, a company that operates the biggest tobacco vaccine facility in the US and that has demonstrated success on monoclonal antibodies for dengue fever and influenza with partner United Therapeutics.
The full story is at: http://www.nasdaq.com/article/should-ebola-fear-tobacco-cm403618.
More tobacco money could be used to help fight all cancers in England from next year.
The UK’s Labour Party is pledging that, if it wins the next election on May 7, 2015, by 2020 no-one in England will wait more than a week for cancer tests and results, according to a BBC News story on Saturday.
There is currently a recommended six-week limit for diagnostic tests in England, including tests to diagnose cancer.
Labour leader Ed Miliband said the £750 million cost of improving cancer test waiting times would be covered by a levy on tobacco firms.
Labour’s proposal to levy an additional tax on the UK’s tobacco companies was initially announced towards the end of last month.
Miliband told delegates at Labour’s annual party conference in Manchester that it was fair to impose additional costs on an industry that made “soaring profits on the back of ill health”.
At that time, Imperial Tobacco reacted by saying that Labour’s plans to tax companies according to their market shares amounted to an attack on a legitimate business sector.
A spokesman for the company said the idea was totally unwarranted and unjust, and should be dismissed immediately.